据了解，通过整合嘉和生物的创新研发资源，亿腾医药将能够加速创新药物的研发和市场推广。特别是嘉和生物即将上市的CDK4/6抑制剂来罗西利，能与亿腾医药现有的HDAC抑制剂景助达形成联动效应，共同开拓更广阔的市场空间。除了在国内市场发力外，嘉和生物与亿腾医药还将目光投向了海外市场。嘉和生物与亿腾医药的合并，将为双方未来的海外市场拓展奠定坚实的基础。GENOR-B (06998) rose nearly 10% against the market trend. As of the time of writing, it has increased by 9.83%, trading at 1.9 Hong Kong dollars, with a transaction amount of 1.8356 million Hong Kong dollars.
According to the Zhitong Finance APP, GENOR-B (06998) has risen nearly 10% against the market trend. As of the time of writing, it is up 9.83%, priced at 1.9 Hong Kong dollars, with a transaction volume of 1.8356 million Hong Kong dollars.
In terms of news, recently, GENOR announced a merger agreement with E-Town Pharmaceuticals. According to the agreement, E-Town Pharmaceuticals will become a wholly-owned subsidiary of GENOR through a reverse acquisition and will be renamed "E-Town GENOR Pharmaceutical Group Co., Ltd." This marks the first reverse acquisition case of an innovative drug company since the HKEX issued the 18A rule, signifying another major breakthrough for E-Town Pharmaceuticals in the Capital Markets.
It is understood that by integrating GENOR's innovative research and development resources, E-Town Pharmaceuticals will be able to accelerate the development and market promotion of Innovative Drugs. In particular, GENOR's upcoming CDK4/6 inhibitor, Lorisil, can create a synergistic effect with E-Town Pharmaceuticals' existing HDAC inhibitor, Jingzhuda, to jointly explore a broader market space. In addition to focusing on the domestic market, GENOR and E-Town Pharmaceuticals are also looking towards the overseas market. The merger between GENOR and E-Town Pharmaceuticals will lay a solid foundation for both parties' future expansion in overseas markets.
